# US 2024/0197986 A1 · Multi-stage biodegradable drug delivery platform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197986 A1
- Document ID: US20240197986A1
- Status: Published application
- Kind: A1
- Application number: 18/584,621
- Filed: 2024-02-22
- Published: 2024-06-20
- Earliest claimed: 2013-03-15
- Assignees: InCube Labs, LLC
- Applicants: InCube Labs, LLC
- Inventors: Mir IMRAN
- Web page: https://patentgrep.com/patent/US20240197986A1

## CPC

- A61M 5/158: Needles {for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body}
- A61D 1/025: {Vaccination appliances (hypodermic syringes A61M)}
- A61D 7/00: Devices or methods for introducing solid, liquid or gaseous remedies or other materials into or onto the bodies of animals (for reproduction or fertilisation A61D19/00)
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61M 2202/064: Powder
- A61M 2202/30: Vaccines
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61D: VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A multi-stage biodegradable drug delivery platform, comprising:
a body including a first biodegradable structure having a primary cavity containing a first dosage of therapeutic agent, and a second biodegradable structure having a secondary cavity containing a second dosage of therapeutic agent, the second biodegradable structure contained in the primary cavity of the first biodegradable structure, the second biodegradable structure comprising a shell having a shell wall with a thickness of about 1 to about 20 thousandths of an inch and a weight of about 90 mg to about 150 mg, the shell wall having a material composition selected to time a release of the second dosage to a specified time subsequent to a release of the first dosage.

### Claim 22 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the first biodegradable structure is configured to biodegrade in vivo over a first time period to release the first dosage of therapeutic agent, and the second biodegradable structure is configured to biodegrade over a second time period to release the second dosage of therapeutic agent.

### Claim 23 (depends on 22)

The multi-stage biodegradable drug delivery platform of claim 22, wherein the second time period is longer than the first time period.

### Claim 24 (depends on 22)

The multi-stage biodegradable drug delivery platform of claim 22, wherein the body and the shell are configured such that there is substantially no release of therapeutic agent between the first time period and the second time period.

### Claim 25 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the body includes a pointed end configured to allow the body to penetrate skin of a patient.

### Claim 26 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the body is at least partially hollow.

### Claim 27 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the first dosage and the second dosage comprise the same therapeutic agent.

### Claim 28 (depends on 27)

The multi-stage biodegradable drug delivery platform of claim 27, wherein the first dosage and the second dosage comprise different amounts or concentrations of the same therapeutic agent.

### Claim 29 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the body is configured to release the first dosage of therapeutic agent as a bolus dose.

### Claim 30 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the first dosage and the second dosage comprise a vaccine.

### Claim 31 (depends on 30)

The multi-stage biodegradable drug delivery platform of claim 30, wherein the second dosage of vaccine is a booster dosage.

### Claim 32 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the first dosage and the second dosage comprise an antibiotic.

### Claim 33 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the second biodegradable structure has a material composition different from the first biodegradable structure.

### Claim 34 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the first biodegradable structure and the second biodegradable structure have different rates of in vivo biodegradation.

### Claim 35 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the first biodegradable structure comprises a sugar or maltose.

### Claim 36 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, wherein the second biodegradable structure comprises magnesium or a magnesium alloy.

### Claim 37 (depends on 21)

The multi-stage biodegradable drug delivery platform of claim 21, further comprising a third cavity coupled to the second biodegradable structure, the third cavity being defined by a second shell wall for containing a third dosage of therapeutic agent, the second shell wall having a thickness and material composition selected to time a release of the third dosage to a specified time subsequent to the release of the second dosage.

### Claim 38 (depends on 37)

The multi-stage biodegradable drug delivery platform of claim 37, wherein a portion of the second shell wall defines a shared wall between the secondary cavity and the third cavity.

### Claim 39 (depends on 37)

The multi-stage biodegradable drug delivery platform of claim 37, wherein the first dosage, the second dosage, and the third dosage comprise the same therapeutic agent.

### Claim 40 (depends on 39)

The multi-stage biodegradable drug delivery platform of claim 39, wherein the first dosage, the second dosage, and the third dosage comprise different amounts or concentrations of the same therapeutic agent.
